NSEPrice movement10 Sept 2026 · 10 Sept 2026, 06:15 pm

Price movement

Bal Pharma Limited · BALPHARMA

✦ AI SummaryRegulatory

Bal Pharma Limited has responded to a query from the NSE regarding significant price movement in its shares, stating that it does not have any price-sensitive information and has made all necessary disclosures under SEBI regulations.

Analysis Scores

Earnings Impact1/10
Growth Catalyst1/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Significant movement in price has been observed in Bal Pharma Limited. The Exchange, in order to ensure that investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Bal Pharma Limited has submitted their response.

Attachments (1)

📄

BALPHARMA1_10092026181525_Clarifications_.pdf

pdf

Download →
View document text
To To Date: September 10, 2026 Listing Compliance Department BSE Limited National Stock Exchange of India Limited, 1st Floor, New Trading Ring, Exchange Plaza, 5th Floor, Plot No. C/2, G Rotunda Building, P.J. Towers, Block, Dalal Street, Bandra Kurla Complex, Bandra (E), Mumbai – 400001 Mumbai-400051 Symbol: BALPHARMA Scrip Code: 524824 Sub: Clarification regarding Movement in Price With reference to NSE Letter Ref No : NSE/CM/Surveillance/17537 and BSE Letter Ref No : L/SURV/ONL/PV/SJ/2026-2027 /4239 dated 10th September, 2026 received through email, regarding significant movement in the price of the Company’s scrip on Stock exchange. In this connection, we wish to inform you that we do not have price sensitive information / material information which can result / has resulted significant movement in price of the Company’s scrip. Further, Company has made all the disclosures under SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, within the stipulated time period which may have a possible impact / fluctuation on the price of the Company's scrip. We confirm that as on the date of this letter, there is no event / information / announcement that need to be reported to the Stock Exchange. The volatility in the price of the Company’s scrip on the Stock Exchange is purely natural and market driven. We further submit that the Company is not aware of any specific reason for the significant movement in the price of its security. Such movement is purely market driven and may be attributable to a combination of factors, including prevailing market conditions. The management of the Company is in no way connected with the movement in the share price. We would like to reiterate that the Company has always adhered to, and will continue to adhere to, the compliance requirements under the Listing Regulations and other applicable laws, and will continue to make disclosures to the Stock Exchanges as and when required. Kindly take the same on your record. Thanking You. For Bal Pharma Limited Shreepada ML Company Secretary and Compliance officer ICSI M No : A66681